阿托伐他汀对血脂异常的非糖尿病患者血清脂联素和炎症因子的影响

Effects of atorvastatin on adiponectin and inflammatory markers in non-diabetic patients with dyslipidaemia

目的探讨血脂异常的非糖尿病患者给予阿托伐他汀治疗后血清脂联素(APN)和炎症因子的变化。方法 20例血脂异常的非糖尿病患者,予阿托伐他汀20mg/d,连服12周;于服药前、服药4周和12周时抽取空腹静脉血,分别测定总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、血清APN、高敏C反应蛋白(hs-CRP)、TNF-α和IL-6。结果与治疗前比较,用药4周后,患者TC、LDL-C、hs-CRP、TNF-α、IL-6明显降低(P<0.01),HDL-C、血清APN明显升高(P<0.01)。继续服药至12周,TC、LDL-C进一步下降至治疗目标值(分别<5.2mmol/L和3.3mmol/L),而炎症因子无明显变化。结论阿托伐他汀治疗可明显降低TC、LDL-C、hs-CRP、TNF-α和IL-6,升高血清APN水平。

Objective To evaluate the effects of atorvastatin therapy on serum adiponectin（APN） and the inflammatory markers in hyperlipidemic patients. Methods Twenty non-diabetic patients with dyslipidaemia were treated with atorvastatin 20mg/d for 12 weeks.The criteria measued included total cholesterol（TC）,low-density lipoprotein cholesterol（LDL-C）,high-density lipoprotein cholesterol（HDL-C）,triglycerides（TG）, APN,high-sensitivity C-reactive protein（hs-CRP）,tumor necrosis factor-α（TNF-α） and interleukin-6（IL-6） before and at 4 and 12 weeks after treatment. Results Compared to before,TC,LDL-C,hs-CRP,TNF-α and IL-6 were decreased（P〈0.01）,HDL-C and APN were increased（P〈0.01） at 4 weeks after treatment.After 12 weeks of treatment,TC and LDL-C decreased further to the goal levels of less than 5.2mmol/L and 3.3mmol/L,respectively,without any significant changes in the inflammatory markers. Conclusion Atorvastatin can significantly decrease TC,LDL-C,hs-CRP,TNF-α and IL-6,and increase serum APN.